Analytical Data
-
基因名
FGFR-1 beta (IIIb)
-
简介
FGFR-1 beta is a member of the FGFR family that interacts with fibroblast growth factors and regulates mitosis and differentiation. It specifically binds acidic and basic fibroblast growth factors and is involved in limb induction. FGFR-1 beta (IIIb) Protein, Human (HEK293, His) is a recombinant protein dimer complex containing human-derived FGFR-1 beta, expressed by HEK293 , with C-His labeled tag. FGFR-1 beta (IIIb) Protein, Human (HEK293, His), has molecular weight of 45-60 kDa.
- Application
-
别名
Fibroblast growth factor receptor 1; FGFR-1; FGF R1b; FGFR1 beta
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11362-14
-
表达区间
P11362-14/NP_075594.1 (R22-K221&A270-E285)&AAB19502 (H1-P47)
-
分子量
45-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FGFR-1 beta (IIIb) is an important member of the fibroblast growth factor receptor (FGFR) family, which plays a crucial role in various biological processes, including cell proliferation, differentiation, and survival. Dysregulation of FGFR signaling has been implicated in numerous pathological conditions, particularly in cancer. The FGFR-1 variant beta (IIIb) is specifically associated with epithelial cell functions and is often expressed in tissues where signaling is critical for normal development and maintenance. Research into FGFR-1 beta (IIIb) has gained momentum due to its potential as a therapeutic target in diseases characterized by aberrant FGFR signaling, especially in cancers such as breast, lung, and bladder cancer. Understanding the structure and function of FGFR-1 beta (IIIb) can aid in the development of targeted therapies that inhibit its activity, thus providing a novel approach to cancer treatment. Recombinant protein studies of FGFR-1 beta (IIIb) aim to elucidate its interactions with various ligands and signaling pathways, thereby advancing our knowledge of its biological roles and paving the way for innovative therapeutic strategies. As research progresses, the characterization of FGFR-1 beta (IIIb) as a drug target holds promise for improving clinical outcomes for patients with FGFR-related malignancies.
